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Introduction
Nuclear inclusions/aggregates
Possible targets for therapy:
- Blocking testosterone/DHT
- Intra-nuclear 
Katsuno et al., 2004
Polyglutamine (polyQ) tract in the 
androgen receptor




The mechanism of pathogenesis in SBMA is through gain-of-function toxicity 
through aberrant intra-nuclear AR-protein interactions. 
• Research objectives/questions:
- Develop an AR interactome in an established PC12 cell model of SBMA
- Investigate which intra-nuclear proteins and protein networks are affected through 
interaction with polyQ AR vs WT
- Validate new therapeutic targets
AR-mutant cell lines
- Ligand-bound C-terminus AF2 interacts with the N-terminal FxxLF à this 
interaction is required for disease
- Mutation of a single NTD amino acid F23A is neuroprotective (prevents N-C 
interaction, nuclear aggregates and toxicity)
- Another amino acid (S16) is phosphorylated in the F23A cells à mediates 
this neuroprotective effect
- Mutation of serine à alanine (S16A) completely abrogates this effect
Final cell lines: 
AR112Q-F23A (non-toxic) vs AR112Q-F23A/S16A (toxic)
Review of Methods
• SILAC – to develop the AR interactome and 
identify new therapeutic targets
• Validation studies:
– Western Blot
– Proximity Ligation Assay 
Methods: SILAC design




Zhang and Neubert, 2009
SILAC Results
Protein Name Gene Name













rase Pde2a C21(3) no 7.397759853
Protein 
NDRG1 Ndrg1 C21(3) HC(3) 6.330527024
Trappc9 C21(2) HC(1) 6.236868261









l regulator 1 Ifrd1 C21(2) HC(2) 3.293774031
Glutathione S-
transferase 
theta-2 Gstt2 C21(2) no 3.271360967
Gbe1 C21(3) HC(3) 3.175194645
Protein Name Gene Name









t subunit C C1qc C18(2) no 17.2711182
5-nucleotidase Nt5c3a C18(2) HC(1) 7.277219201
Itpk1 C18(2) HC(1) 6.684430452
Ssh2 C18(2) HC(1) 5.826532345










form Chgb C18(3) HC(3) 3.396413917
Complement 
C3 C3 C18(2) HC(3) 3.158706834
C21 (control) C18 (SBMA)



























































































































- no significant difference in DDC expression between the two cell lines à implies that SILAC results 
weren’t because of a difference in total amount of DDC










Mean gray value = sum of the gray values of all the pixels 
in the selection divided by the number of pixels
Note: white = 0, black = 250
*Kolmogorov-Smirnov test 
Opposite of what we expected from 
the SILAC screen!
Two populations of cells - cells with 
minimal AR-DDC interactions and cells with 
a very high number of interactions
Conclusions
• The SILAC screen gave us a large number of proteins that 
interact with the mutant poly-Q AR, all of which have the 
potential to be targeted for SBMA therapeutics.
• We chose dopa decarboxylase (DDC) to further validate via 
WB and PLA, however our initial validation studies showed an 
inverse relationship to what we expected from the screen.
• There is currently no known treatment for SBMA and very 
little known about the disease process, so we hope this study 
will be a stepping-stone towards answering some of those 
questions.
Future directions
• Repeat PLA in conjunction with IF for both AR and DDC 
(possible variations in AR/DDC expression between the highly 
interactive and less interactive cells skewing the results?)
• Validate other targets from the SILAC screen
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